Also, don’t miss Daniel Haag’s presentation on Wednesday. He will be presenting data on how NeuCyte’s SynFire technology is accelerating CNS Drug Discovery and Neurotox Assessments.
Addressing Relevant Physiological Readouts for CNS Drug Discovery
Daniel Haag, Ph.D., CSO, NeuCyte
NeuCyte Inc. is a biotechnology company focusing on early phases of CNS drug discovery. Based on our SynFireTM technology, we have developed a proprietary human neural in vitro platform for complex electrophysiological and morphological readouts suited for target identification and validation, efficacy testing and neurotoxicity assessment. Using patient-derived and genetically engineered defined neural cell types, NeuCyte builds unique cell-based assays for modelling neurological and neurodegenerative disorders.